BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; Helicobacter pylori–the gastric ulcer bacterium; low bone density; and diverticulitis, as well as baby and child gut, adult gut, immune, pregnancy, oral, and bone health. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
|Average||131.50 (+27.92% Upside)|
|No. of Analysts||2|